CPHA part of the GFCT Charity are pleased to offer FREE blood pressure and basic Kardia ECG tests at our future health test events in Cornwall, starting at our Liskeard event on the 1st February.
These tests can act as indicators of potentially serious underlying health conditions, some of which may lead to a stroke in the future.
This exciting initiative is led by Helen Dale-Sleeman who is a Specialist Stroke Nurse and East Team Lead at the Cornwall Partnership NHS Foundation Trust. Helen and her team will carry out the tests at our health events and will be happy to talk it through with you on the night.
There is no need to pre-book the blood pressure and Kardia ECG tests but to be eligible you need to register for at least one of the other health tests on offer at the event, details of future events and how to register can be found here.
Please take advantage of this opportunity and avoid being one of the estimated over half a million people in the UK putting their health at risk by not knowing they have high blood pressure.
PCUK HAVE ANNOUNCED THEIR INTERIM POSITION ON PSA TESTING – NOVEMBER 2022
Following a review of new evidence and two co-production workshops including men with lived experience, academics, and clinicians, we have agreed some key changes in what we think and say about the PSA blood test for men without symptoms. This is an interim position because a large-scale epidemiological study of PSA blood test use in the UK and an evidence review are currently underway; our position will continue to evolve in response to our findings.
Since the 2019 NICE guidance updatei, the prostate cancer diagnosis and treatment pathway changed to make it safer and more accurate.
The PSA blood test is the first step in the prostate cancer diagnostic pathway. It is a cheap, safe and effective way of identifying men who would benefit from further testing – in the first instance an MRI scan.
There isn’t a national screening programme for prostate cancerxii, so men won’t get invited to have a test. Men at risk, have a right to a PSA blood test for free from their GP if they want onexiv.
The risks from over-diagnosis and over-treatment of prostate cancer have reduced to a point where we believe GPs should proactively engage higher-risk men, about the PSA blood test.
The individual benefits of a PSA blood test will be different for each man. This is because some men will have more risk factors than others or will have pre-existing health conditions. Information or counselling on the PSA blood test should explain this.
Our role, alongside the NHS, is to reach and activate higher-risk men and support them to make an informed choice about whether to have a PSA blood test. We can achieve this through partnership awareness campaigns and our risk checker.
Because Black men have double the risk of prostate cancer and develop it younger, we strongly recommend they talk to their GP about a regular PSA blood test from the age of 45. As a Black man, if you are worried about prostate cancer, you can speak to a GP from any age.
Men with a known family history of prostate, breast, or ovarian cancer – in particular if a first degree relative has died of these cancers – are at higher risk and we strongly recommend they talk to their GP about a regular PSA blood test from the age of 45.
Black Men with a known family history of prostate, breast, or ovarian cancer – in particular if a first degree relative has died of these cancers – are at the highest risk and should seriously consider PSA blood testing at an earlier age.
One normal PSA result can’t rule out a future diagnosis of prostate cancer. Regular PSA tests can spot trends in PSA levels.
The European Commission is calling for prostate cancer screening in men up to 70 on the basis of PSA testing, and magnetic resonance imaging (MRI) scanning as follow-upxxxiii,xxxiv, The recommendations are backed by a combination of evidence from randomised controlled trials and real-world studiesxxxv. We believe this provides good evidence to change current practice but acknowledge that some evidence gaps remain.
Should this recommendation be ratified in Europe, we would urgently call on the UK National Screening Committee to review this evidence in a UK-specific context and assess whether the proposed framework for screening should also be rolled out in the UK.
“Life-changing” recommendations by European Commission for men impacted by Prostate CancerProstate cancer patients, clinicians and researchers jointly praised the European Commission’s decision to extend a recommendation of organised cancer screening programmes to prostate cancer. The Commission has today published the update of the 2003 EU Council Screening Recommendations which adds prostate, lung and gastric cancers to the list to be addressed by the cancer screening recommendations (on top of breast, colorectal and cervical cancer).
In its update, the Commission has added Prostate Cancer to the list of programmes that will benefit from European guidelines and quality assurance work. The Commission also commits to supporting research on cancer screening, strengthening cooperation between EU Member States and overcoming legal and technical barriers to data sharing to support screening.
It now falls to EU Member States to accept these Recommendations and swiftly implement them in their own populations to save lives. This marks a great success of the EAU Policy Office’s advocacy campaign, partnered with patients, researchers, national societies on raising awareness of early detection of prostate cancer.
Günther Carl, Chairman, Europa Uomo “For us, this recommendation to add prostate cancer screening to the list of cancers addressed by EU-wide guidance will be life-changing for men whose lives are impacted by prostate cancer. Many of us are only alive and active today because our cancers were detected early by elevated PSA levels. Prostate cancer has been a silent killer for too long. It also negatively impacts the quality of life of too many men and their families. Our patient-led surveys have shown that the best quality of life is obtained by men who have caught their cancer early and who can be treated on active surveillance or, if their cancer is of higher risk, with active treatment. Those patients with aggressive cancers that are caught too late, will suffer from many more side effects. We are delighted to see that prostate cancer has been added to the list.”
Prof Hendrik Van Poppel, Chair of the European Association of Urology’s Policy Office “We warmly welcome the European Commission’s proposal to include PSA-based prostate cancer screening with a risk-adapted approach for follow-up in the update of the EU Screening Recommendations. Prostate cancer is the most common form of male cancer and is a serious condition that kills over 100,000 men each year in Europe. We are really excited to see the European Commission taking this approach.”
“We will now work closely with our National Urological Societies to support their national authorities to swiftly implement this recommendation and hope the “step-wise” approach to implementation will not lead to unnecessary delays. It means that we can catch aggressive cancers early, helping us to ensure men do not suffer and die from this disease unnecessarily. Additionally, the risk-adapted follow-up will help eliminate the concerns of overdiagnosis and over treatment. We are sure this approach will help us as clinicians to ensure better outcomes for men with prostate cancer.”
Prof Monique Roobol, Principal Investigator of the European Randomised Study for Screening of Prostate Cancer (ERSPC), Erasmus University Medical Centre “The evidence generated by over 20 years of data coming from ERSPC shows that when PSA-based screening is well organised, there is a significant drop in mortality. The new tools which we have at our fingertips such as risk calculators and MRI make it easier to prevent overtreatment and overdiagnosis which was previously the argument against prostate cancer screening. This recommendation, taken on the basis of the opinion of the Commission’s Chief Scientific Advisors is a real milestone – it would mean that we could move forward with implementation of good quality screening programmes in Europe, resulting is less deaths from prostate cancer and a better quality of life for those touched by the condition.”
Thanks for the reminder. Following my last PSA test (which came back as a 4), my GP was reluctant to refer me at first as I hadn’t had the test through them and had no history of prostrate cancer. I wasn’t seen by my GP but when I persisted, I was referred to my local urology unit. They acted very quickly and sent me for further tests, eventually ending up been diagnosed with stage 3 prostrate cancer in May.
I had a robotic Prostatectomy in August last year.
During the various tests the urology unit picked up I also had stage 2 kidney cancer in my left kidney. I underwent a partial Nephrectomy on New Years eve.
I am now cancer free!
I’d like to pass on my sincere gratitude to your team and the work that you do. Without it my life span and quality of life would be greatly reduced.
“The National Prostate Cancer Audit 2021 from England and Wales published last week found the number of patients being diagnosed with prostate cancer fell 54% in England between April and June 2020 highlighting the staggering impact the pandemic has had on detecting other serious diseases.
Of the men diagnosed with Prostate Cancer since April 2020 a higher proportion – 21% versus 17% – were diagnosed at the most advanced stage compared with the previous year.
Prostate Cancer is now the most common cancer in the UK with 57,000 new cases each year.
I just want to let you know I got my results last Friday, they have come back that I have prostate cancer, not a very nice early Christmas present😭.
I just want to say thank you to you and the team for giving me the chance to be tested, I know it’s crap that I have cancer but if it wasn’t for you guys I would be walking oblivious doing my normal daily work etc and the cancer would be growing and spreading round my body.
I am going into the Freeman hospital to my prostate removed within the next five weeks.
I am worried sick but I know I’ll be ok.
Again thank you. Phillip Cavaghan 54 from Penrith xx
This video has been made by North Wales Police following two years of testing within their force. We have worked very closely with Maria Hughes who is Corporate Head of Medical Services. This video is the real life story of Neil Akers who is the Force Risk and Business Continuity Head, who explains his real life experience following a routine PSA blood test, his visit to his GP and eventually finding out he had agressive cancer. His words are, “If I hadn’t taken the test I would not see December 2021“.
We are undertaking a major research study into PSA and Free to Total scoring working alongside the University of Manchester. This important research commenced in January 2021, with the aim of finishing in two to three years. We hope this research will help persuade the Health Authorities to implement a National Prostate Cancer Screening Programme for all men in the UK.
If you would like to help us achieve this, we would ask you to participate by completing the questionnaire by clicking this link.
Please share this video on social media and ask anyone you know who has had prostate cancer or been tested for prostate cancer, to take part in our research.
Tracer is injected into the bloodstream and lights up metastatic prostate cancer cells during PET scanHealthDay
FRIDAY, May 28, 2021 (HealthDay News) — A new imaging agent that detects prostate cancer that has spread to other parts of the body has been approved by the U.S. Food and Drug Administration.
The tracer will help doctors find metastatic prostate cancer cells that are difficult to detect with traditional imaging methods, Michael Morris, M.D., a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City who was involved in clinical trials of the tracer, told NBC News.
He noted that when prostate cancer spreads, it often goes into the bones and it is “really hard to take pictures of what’s going on inside of bone.” With the new tracer, we “can detect it much more clearly and much earlier than we could before,” he told NBC News.
The tracer from medical imaging company Lantheus is injected into the bloodstream and lights up metastatic prostate cancer cells during a positron emission tomography scan.
The new tracer — the first for advanced prostate cancer that is commercially available across the United States — is not meant to replace the prostate-specific antigen blood test, NBC News reported.
This study presented 2-year follow-up data of a randomised trial comparing prostate artery embolisation (PAE) with transurethral resection of the prostate (TURP) among men with refractory symptoms secondary to benign prostatic hyperplasia with prostate sizes 25 to 80 cc, International Prostate Symptoms Score (IPSS) >7, quality-of-life score >2, and Qmax <12 mL/s. In all, 103 patients were initially randomised, 51 to PAE and 52 to TURP, with 34 (PAE) and 47 (TURP) having available data for analysis at 2 years. In the PAE group, mean IPSS decreased from 19 to 10 at 3 months and remained at 10 for 2 years. In the TURP group, IPSS decreased from 18 to 7 at 3 months and was 5 at 2 years. Men undergoing TURP reported greater decreases in quality of life, which continued to improve over 2 years in the TURP group; the scores were stable in the PAE group.
Given greater loss to follow-up in the PAE group, benefits of TURP relative to PAE were probably underestimated. As such, these study results suggest that, although PAE may be advantageous as far as perioperative morbidity goes, it cannot match the benefit associated with TURP.
This study is the best evidence to date in support of PAE for treating symptomatic BPH. The 3-month results had confirmed good symptomatic early outcomes compared with TURP but inferior relief of obstruction, as you would expect. The maintenance of these results out to 24 months is an important feature of this paper, but the fact that 21% of patients in the PAE group required TURP due to “unsatisfying clinical outcomes” is the most telling finding. Durability predictably, has become the Achilles heel of many of the newer minimally invasive therapies, most notably the UroLift device, and it appears that this is going to be a significant problem for PAE as well.